FDA Warns Sanofi Over Taxotere Marketing Claims

Law360, New York (May 13, 2009, 12:00 AM EDT) -- The U.S. Food and Drug Administration has warned Sanofi-Aventis over including what regulators have said are misleading statements in marketing materials for the breast cancer treatment Taxotere that tout the treatment over paclitaxel, which is sold by Bristol-Myers Squibb Co. under the brand name Taxol.

In a letter released Wednesday, the FDA chastised the French drugmaker for disseminating a reprint of an article from the Journal of Clinical Oncology describing a study that regulators say overstates the effectiveness of the drug.

The article claimed Taxotere was...
To view the full article, register now.